Get the Stockscreener App
36.14
5.52%
1.89
Pre-market:
36.45
0.31
+0.86%
Crispr Therapeutics Ag stock is traded at $36.14, with a volume of 2.48M.
It is up +5.52% in the last 24 hours and up +15.57% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$34.25
Open:
$34.88
24h Volume:
2.48M
Relative Volume:
1.13
Market Cap:
$3.26B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-12.91
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-4.21%
1M Performance:
+15.57%
6M Performance:
-29.99%
1Y Performance:
-32.18%
1-Day Range:
$34.12
$36.86
1-Week Range:
$33.03
$39.38
52-Week Range:
$30.04
$67.88
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
36.14 | 3.26B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.60 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.67 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
569.12 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.35 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
235.94 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines - Seeking Alpha
Crispr Therapeutics (CRSP) Price Target Reduced by Barclays to $42 | CRSP Stock News - GuruFocus
CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million - Yahoo Finance
CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results - insights.citeline.com
CRISPR Therapeutics (CRSP): Goldman Sachs Lowers Price Target to $47 | CRSP Stock News - GuruFocus
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
June 27th Options Now Available For CRISPR Therapeutics - Nasdaq
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet - Yahoo
CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade) - Seeking Alpha
Bridgefront Capital LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Promising Developments and Pipeline Expansion at Crispr Therapeutics AG Support Buy Rating - TipRanks
Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP) - The Globe and Mail
CRSP: Needham Maintains Buy Rating Despite Target Price Reductio - GuruFocus
Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course (NASDAQ:CRSP) - Seeking Alpha
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst - Benzinga
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRS - GuruFocus
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks - MSN
Crispr Therapeutics price target lowered to $79 from $80 at BofA - TipRanks
CRSP Sees Price Target Adjustment by BofA Amid Key Updates | CRSP Stock News - GuruFocus
CRSP: Needham Maintains Buy Rating Despite Target Price Reduction | CRSP Stock News - GuruFocus
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results - Benzinga
CRSP Stock: Analyst Maintains Buy Rating, Lowers Price Target | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Trial Results and Strong Financial Position Support Buy Rating - TipRanks
Crispr Therapeutics AG: Strong Buy Rating Backed by Promising Clinical Data and Strategic Collaborations - TipRanks
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - Yahoo Finance
Crispr Therapeutics (CRSP) Upgraded to Buy by Clear Street Analyst | CRSP Stock News - GuruFocus
Crispr Therapeutics upgraded to Buy from Hold at Clear Street - TipRanks
Crispr Therapeutics AG: Balancing Growth Potential with Profitability Challenges – Hold Rating - TipRanks
NKureCRISPR Therapeutics partner to develop off-the-shelf CAR-T therapy - BusinessLine
NkureCrispr Therapeutics partner to co-develop off-the-shelf CAR-T therapy - BusinessLine
NKure Therapeutics and CRISPR Therapeutics Partner to Advance CTX112 for Cancer Treatment in India - APN News
Dimensional Fund Advisors LP Has $37.28 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Nkure Therapeutics And CRISPR Therapeutics Partner To Advance CTX112™ For Cancer Treatment In India - Passionate In Marketing
Decoding CRISPR Therapeutics AG (CRSP): A Strategic SWOT Insight - GuruFocus
CRISPR (CRSP) Reports Wider Losses Amid Revenue Growth - GuruFocus
Crispr Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
CRISPR Therapeutics AG reports results for the quarter ended March 31Earnings Summary - TradingView
CRISPR Therapeutics AG Reports Q1 2025 EPS of -$1.58 and Revenue of $865K, Missing Estimates - GuruFocus
Biotechnology: Crispr Therapeutics starts the year with higher loss | blue News - bluewin E-Mail
Crispr Therapeutics reports Q1 EPS ($1.58), consensus ($1.28) - TipRanks
CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 - The Manila Times
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened - Yahoo Finance
Baker BROS. Advisors LP Buys 464,936 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts - Seeking Alpha
Genome Engineering Market Generated Opportunities, Future - openPR.com
Susquehanna Fundamental Investments LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
Barclays PLC Sells 27,790 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Raymond James Financial Inc. Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.73%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):